Interleukin-21 as a new therapeutic target for immune-mediated diseases

Trends in Pharmacological Sciences

Volumn 30, Issue 8, 2009, Pages 441-447

  Monteleone, Giovanni ^a   Pallone, Francesco ^a   Macdonald, Thomas T ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR6; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; INTERKEULIN 21 RECEPTOR ANTAGONIST; INTERLEUKIN 12P40; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; JANUS KINASE 1; JANUS KINASE 3; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; UNCLASSIFIED DRUG;

ATOPIC DERMATITIS; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; COLITIS; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG TARGETING; ENTERITIS; ENZYME INACTIVATION; EPITHELIUM CELL; FIBROBLAST; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MEDICAL RESEARCH; NATURAL KILLER CELL; NONHUMAN; NORTHERN BLOTTING; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TISSUE INJURY;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTERLEUKINS; MODELS, IMMUNOLOGICAL; SIGNAL TRANSDUCTION;

EID: 67849120058     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.05.006     Document Type: Review

References (69)

1. Joffre O., et al. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol. Rev. 227 (2009) 234-247
2. Feldmann M. Many cytokines are very useful therapeutic targets in disease. J. Clin. Invest. 118 (2008) 3533-3536
3. Chong B.F., and Wong H.K. Immunobiologics in the treatment of psoriasis. Clin. Immunol. 123 (2007) 129-138
4. Ebert E.C. Infliximab and the TNF-α system. Am. J. Physiol. Gastrointest. Liver Physiol. 296 (2009) G612-G620
5. Ding C., and Jones G. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases. Rev. Recent Clin. Trials 1 (2006) 193-200
6. Tayal V., and Kalra B.S. Cytokines and anti-cytokines as therapeutics-an update. Eur. J. Pharmacol. 579 (2008) 1-12
7. Parrish-Novak J., et al. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J. Leukoc. Biol. 72 (2002) 856-863
8. Ozaki K., et al. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 11439-11444
9. Parrish-Novak J., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408 (2000) 57-63
10. Spolski R., and Leonard W.J. The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr. Opin. Immunol. 20 (2008) 295-301
11. Intlekofer A.M., et al. 10: Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science 321 (2008) 408-411
12. Coquet J.M., et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J. Immunol. 178 (2007) 2827-2834
13. Vogelzang A., et al. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 29 (2008) 127-137
14. Monteleone G., et al. Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. Trends Immunol. 29 (2008) 290-294
15. van Heel D.A., et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat. Genet. 39 (2007) 827-829
16. Festen E.A., et al. Genetic variants in the region harbouring IL2/IL21 associated to ulcerative colitis. Gut 58 (2009) 799-804
17. Asano K., et al. Molecular scanning of interleukin-21 gene and genetic susceptibility to type 1 diabetes. Hum. Immunol. 68 (2007) 384-391
18. Liu Y., et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 4 (2008) e1000041
19. Chatterjee R., et al. A common exonic variant of interleukin21 confers susceptibility to atopic asthma. Int. Arch. Allergy Immunol. 148 (2009) 137-146
20. Sawalha A.H., et al. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann. Rheum. Dis. 67 (2008) 458-461
21. Hecker M., et al. Novel genetic variation of human interleukin-21 receptor is associated with elevated IgE levels in females. Genes Immun. 4 (2003) 228-233
22. Monteleone G., et al. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 55 (2006) 1774-1780
23. Jüngel A., et al. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum. 50 (2004) 1468-1476
24. Caruso R., et al. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology 132 (2007) 166-175
25. Distler J.H., et al. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum. 52 (2005) 856-864
26. Strengell M., et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-γ production in human NK and T cells. J. Immunol. 170 (2003) 5464-5469
27. Fuqua C.F., et al. Involvement of ERK-1/2 in IL-21-induced cytokine production in leukemia cells and human monocytes. Cytokine 44 (2008) 101-107
28. Fantini M.C., et al. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur. J. Immunol. 37 (2007) 3155-3163
29. Peluso I., et al. 14: IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J. Immunol. 178 (2007) 732-739
30. Monteleone G., et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 128 (2005) 687-694
31. Lee Y.K., et al. Late developmental plasticity in the T helper 17 lineage. Immunity 30 (2009) 92-107
32. Nurieva R., et al. Cutting edge: in vitro generated Th17 cells maintain their cytokine expression program in normal but not lymphopenic hosts. J. Immunol. 182 (2009) 2565-2568
33. Caruso R., et al. IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J. Immunol. 178 (2007) 5957-5965
34. Fina D., et al. Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease. Gut 57 (2008) 887-892
35. Jin H., et al. IL-21R is essential for epicutaneous sensitization and allergic skin inflammation in humans and mice. J. Clin. Invest. 119 (2009) 47-60
36. Andersson A.K., et al. Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis. Scand. J. Immunol. 68 (2008) 103-111
37. Fina D., et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 134 (2008) 1038-1048
38. Spolski R., et al. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 14028-14033
39. Sutherland A.P., et al. IL-21 is required for the development of type 1 diabetes in NOD mice. Diabetes 58 (2009) 1144-1155
40. Bubier J.A., et al. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 1518-1523
41. Odegard J.M., et al. ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J. Exp. Med. 205 (2008) 2873-2886
42. Vinuesa C.G., et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 435 (2005) 452-458
43. Young D.A., et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum. 56 (2007) 1152-1163
44. Bubier J.A., et al. Treatment of BXSB-Yaa mice with IL-21R-Fc fusion protein minimally attenuates systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1110 (2007) 590-601
45. Herber D., et al. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J. Immunol. 178 (2007) 3822-3830
46. Fantini M.C., et al. New players in the cytokine orchestra of inflammatory bowel disease. Inflamm. Bowel Dis. 13 (2007) 1419-1423
47. Mannon P.J., et al. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351 (2004) 2069-2079
48. Oppmann B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13 (2000) 715-725
49. Fuss I.J., et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm. Bowel Dis. 12 (2006) 9-15
50. Wang C., et al. The roles of CCR6 in migration of Th17 cells and regulation of effector T-cell balance in the gut. Mucosal Immunol 2 (2009) 173-183
51. Spolski R., et al. IL-21 mediates suppressive effects via its induction of IL-10. J. Immunol. 182 (2009) 2859-2867
52. Konforte D., et al. IL-21: an executor of B cell fate. J. Immunol. 182 (2009) 1781-1787
53. Ettinger R., et al. The role of IL-21 in regulating B-cell function in health and disease. Immunol. Rev. 223 (2008) 60-86
54. Ozaki K., et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J. Immunol. 173 (2004) 5361-5371
55. Mehta D.S., et al. IL-21 induces the apoptosis of resting and activated primary B cells. J. Immunol. 170 (2003) 4111-4118
56. Jin H., et al. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J. Immunol. 173 (2004) 657-665
57. Ozaki K., et al. A critical role for IL-21 in regulating immunoglobulin production. Science 298 (2002) 1630-1634
58. Kasaian M.T., et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16 (2002) 559-569
59. Leonard W.J., et al. Interleukin 21: a cytokine/cytokine receptor system that has come of age. J. Leukoc. Biol. 84 (2008) 348-356
60. Fröhlich A., et al. IL-21 receptor signaling is integral to the development of Th2 effector responses in vivo. Blood 109 (2007) 2023-2031
61. Pesce J., et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J. Clin. Invest. 116 (2006) 2044-2055
62. H17 cells. Nature 454 (2008) 350-352
63. H-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8 (2007) 967-974
64. H17 cells. Nature 448 (2007) 484-487
65. Suto A., et al. Development and characterization of IL-21-producing CD4+ T cells. J. Exp. Med. 205 (2008) 1369-1379
66. Zeng R., et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 201 (2005) 139-148
67. Moroz A., et al. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J. Immunol. 173 (2004) 900-909
68. Fina D., et al. Role of interleukin-21 in inflammation and allergy. Inflamm. Allergy Drug Targets 6 (2007) 63-68
69. Burgess S.J., et al. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells. J. Immunol. 176 (2006) 1490-1497